Evidence map›Paper›PMID 39033372›Full record

ArticleInternational journal of fertility & sterility2024

Improving Fertility in Non-obstructive Azoospermia: Results from an Autologous Bone Mar-row-Derived Mesenchymal Stromal/Stem Cell Phase I Clinical Trial.

Rano Zhankina, Ulanbek Zhanbyrbekuly, Manarbek Askarov, Afshin Zare, Nazanin Jafari, Dana Saipiyeva, Ravil Sherkhanov, Daniyar Akhmetov, Alireza Hashemi, Mojtaba Farjam and 11 more

Abstract read
In one paragraph

Article in International journal of fertility & sterility, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. The Use of Stem Cells in Assisted Reproduction.Journal of clinical medicine · 2025
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Rano Zhankina *Department of Urology and Andrology, Astana Medical University, Astana, Kazakhstan.ORCID 0000-0001-6170-4325
Ulanbek Zhanbyrbekuly *Department of Urology and Andrology, Astana Medical University, Astana, Kazakhstan.ORCID 0000-0003-1849-6924
Manarbek Askarov *National Scientific Medical Center, Astana, Kazakhstan.ORCID 0000-0003-4881-724X
Afshin Zare *Department of R&D Research, PerciaVista R&D Co., Shiraz, Iran.ORCID 0000-0002-1932-8773
Nazanin Jafari *Department of R&D Research, PerciaVista R&D Co., Shiraz, Iran.ORCID 0000-0002-6557-4262
Dana SaipiyevaDepartment of Urology and Andrology, Astana Medical University, Astana, Kazakhstan.ORCID 0000-0003-4270-2679
Ravil SherkhanovDepartment of Urology and Andrology, Astana Medical University, Astana, Kazakhstan.ORCID 0000-0001-7702-4236
Daniyar AkhmetovDepartment of Urology and Andrology, Astana Medical University, Astana, Kazakhstan.ORCID 0000-0003-1866-0288
Alireza HashemiDepartment of R&D Research, PerciaVista R&D Co., Shiraz, Iran.ORCID 0000-0001-7038-3535
Mojtaba FarjamNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.ORCID 0000-0003-4826-2846
Nader TanidehDepartment of R&D Research, PerciaVista R&D Co., Shiraz, Iran.ORCID 0000-0001-9282-1778
Behrouz AflatoonianStem Cell Biology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID 0000-0002-7250-9813
Nadiar Maratovich MussinDepartment of General Surgery, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.ORCID 0000-0003-3600-8840
Asset Askerovich KaliyevDepartment of General Surgery, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.ORCID 0000-0003-4594-4104
Yerlan SultangereyevDepartment of General Surgery, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.ORCID 0000-0002-0610-4906
Hanieh BaneshiDepartment of R&D Research, PerciaVista R&D Co., Shiraz, Iran.ORCID 0000-0000-0000-0000
Reza ShiraziDepartment of Anatomy, School of Biomedical Sciences, Medicine & Health, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-3907-079X
Mahdi MahdipourStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0002-2729-4593
Shabnam BakhshalizadehReproductive Development, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.ORCID 0000-0003-1920-9093
Farhad RahmanifarDepartment of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.ORCID 0000-0001-9585-7266
Amin TamadonDepartment of R&D Research, PerciaVista R&D Co., Shiraz, Iran.ORCID 0000-0002-0222-3035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn this phase I clinical trial, our primary objective was to develop an innovative therapeutic approach utilizing autologous bone marrow-derived mesenchymal stromal/stem cells (BM-MSCs) for the treatment of nonobstructive azoospermia (NOA). Additionally, we aimed to assess the feasibility and safety of this approach. MATERIALS AND

methodsWe recruited 80 participants in this non-randomized, open-label clinical trial, including patients undergoing NOA treatment using autologous BM-MSCs (n=40) and those receiving hormone therapy as a control group (n=40). Detailed participant characteristics, such as age, baseline hormonal profiles, etiology of NOA, and medical history, were thoroughly documented. Autotransplantation of BM-MSCs into the testicular network was achieved using microsurgical testicular sperm extraction (microTESE). Semen analysis and hormonal assessments were performed both before and six months after treatment. Additionally, we conducted an

resultsOur results revealed significant improvements following treatment, including increased testosterone and inhibin B levels, elevated sperm concentration, and reduced levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin. Notably, in nine patients (22.5%) previously diagnosed with secondary infertility and exhibiting azoospermia before treatment, the proposed approach yielded successful outcomes, as indicated by hormonal profile changes over six months. Importantly, these improvements were achieved without complications. Additionally, our

conclusionAutotransplantation of BM-MSCs into the testicular network using microTESE in NOA patients led to the regeneration of seminiferous tubules and the regulation of hormonal profiles governing spermatogenesis. Our findings support the safety and effectiveness of autologous BM-MSCs as a promising treatment modality for NOA, with a particular focus on the achieved outcomes in patients with secondary infertility (registration number: IRCT20190519043634N1).

Indexed as

AzoospermiaClinical trialMesenchymal stem cellsprotein-protein dockingReproductive Techniques

Identifiers

PMID39033372
PMCPMC11263852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.